Barclays lowered the firm’s price target on Baxter to $52 from $54 and keeps an Overweight rating on the shares. The firm updated its sum-of-parts analysis for Baxter and continues to expect the spin-off to create significant shareholder value.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BAX: